Open AccessTwenty-Four-Hour Blood Pressure–Lowering Effect of a Sodium-Glucose Cotransporter 2 Inhibitor in Patients With Diabetes and Uncontrolled Nocturnal Hypertension
Author(s) -
Kazuomi Kario,
Kenta Okada,
Mitsutoshi Kato,
Masafumi Nishizawa,
Tetsuro Yoshida,
Taku Asano,
Kazuaki Uchiyama,
Yawara Niijima,
Tomohiro Katsuya,
Hidenori Urata,
Jun-ichi Osuga,
Takeshi Fujiwara,
Shoji Yamazaki,
Naoko Tomitani,
Hiroshi Kanegae
Publication year - 2019
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.118.037076
Subject(s) - medicine , empagliflozin , ambulatory blood pressure , blood pressure , diabetes mellitus , placebo , morning , body mass index , albuminuria , ambulatory , microalbuminuria , type 2 diabetes , endocrinology , alternative medicine , pathology
The risk of cardiovascular disease and mortality in salt-sensitive patients with diabetes mellitus and uncontrolled nocturnal hypertension is high. The SACRA (Sodium-Glucose Cotransporter 2 [SGLT2] Inhibitor and Angiotensin Receptor Blocker [ARB] Combination Therapy in Patients With Diabetes and Uncontrolled Nocturnal Hypertension) study investigated changes in blood pressure (BP) with empagliflozin plus existing antihypertensive therapy.